Background: In the pancreas, poorly differentiated neuroendocrine carcinomas include small cell carcinoma and large cell neuroendocrine carcinoma and are rare; data regarding their pathologic and clinical features are very limited.
BACKGROUND
With the description of large cell neuroendocrine carcinomas, best characterized in the lung and subsequently recognized in the tubular gastrointestinal tract, the spectrum of poorly differentiated neuroendocrine carcinomas has been extended to include both small cell carcinoma and large cell neuroendocrine carcinoma. 1 On the basis of evidence from both pulmonary and extrapulmonary sites, it appears that these poorly differentiated neuroendocrine carcinomas are highly aggressive neoplasms with a propensity for early metastases and poor outcomes, whether presenting as a pure histologic pattern or as a component of a combined carcinoma. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Poorly differentiated neuroendocrine carcinomas, especially the small cell subtype, also typically have a favorable but short-lived response to platinum-based chemotherapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the literature on poorly differentiated neuroendocrine carcinomas primary in the pancreas is very limited, probably because of the rarity of this disease. Our current understanding of this neoplasm is mainly based on individual case reports, analyses of small series of cases, or opinions presented in textbooks. 1, [11] [12] [13] [14] [15] [16] [17] [18] [19] The diagnostic criteria have also been poorly defined, leading to inconsistent pathologic classification that has impacted clinical management. 20 In the current (2010) World Health Organization (WHO) classification, 1 all pancreatic "high-grade neuroendocrine carcinomas," along with their tubular gastrointestinal tract counterparts, are now included under the grade 3 category, defined by a mitotic rate >20/10 high-power fields (HPF) or a Ki67-labeling index >20%. However, preliminary studies have shown that the grade 3 category includes 2 distinct entities: (1) a more highly proliferative group of well-differentiated neuroendocrine tumors (NETs); and (2) the true poorly differentiated neuroendocrine carcinomas, small cell carcinoma, and large cell neuroendocrine carcinoma. 21 The first group appears to have a significantly more protracted clinical course 21 but less dramatic response to platinum-based chemotherapy 11 compared with poorly differentiated neuroendocrine carcinomas, which have distinctive genetic alterations such as inactivation of TP53 and RB. 22 It is also the impression of many pathologists that true poorly differentiated neuroendocrine carcinomas usually have a very high Ki67-labeling index (typically above 50%), well above the 20% threshold in the current WHO classification 1 for a neuroendocrine neoplasm to be high-grade.
Here, we present one of the largest clinicopathologic studies of pancreatic poorly differentiated neuroendocrine carcinoma, with the aim of further defining the histologic features and clinical outcome in the era of the current WHO classification. Diagnostic issues revealed by our study are also explored.
MATERIALS AND METHODS
Surgical pathology databases of the authors' 14 institutions were searched for cases with a diagnosis of pancreatic "poorly differentiated neuroendocrine carcinoma," "high-grade neuroendocrine carcinoma," "small cell carcinoma," or "large cell neuroendocrine carcinoma" from 1988 to 2012. A total of 107 resections for which the slides were available were identified. Medical records including radiology and pathology reports were reviewed to: (1) obtain clinical data including age, sex, associated genetic syndromes, functionality, distant metastases, and treatment modalities; and (2) exclude the possibility of a metastasis from another organ or direct invasion from a contiguous site, particularly the ampulla of Vater. 23 A representative formalin-fixed paraffin-embedded tissue section of each case was immunolabeled using the standard avidin-biotin peroxidase method with antibodies against the neuroendocrine markers chromogranin A (DakoCytomation, Carpinteria, CA) and synaptophysin (DakoCytomation), the acinar differentiation markers trypsin (Biodesign, Memphis, TN) and chymotrypsin (Biodesign), and Ki67/MIB1 (DakoCytomation). Five cases revealed sheets of small, round, monotonous cells with a syncytial appearance and small pseudorosettes; these cases were also immunolabeled for CD99 (DakoCytomation) to explore the alternative diagnosis of primitive neuroectodermal tumor (PNET). The slides were then reassessed using the diagnostic and grading criteria put forth in the current (2010) WHO classification of neuroendocrine neoplasms of the digestive system. 1 Specifically, small cell carcinomas were characterized by sheets or nests of relatively small cells with a high nucleus-to-cytoplasm ratio, hyperchromatic and finely granular chromatin, inconspicuous nucleoli, and nuclear molding. Large cell neuroendocrine carcinomas displayed neuroendocrine architectural patterns (ie, organoid or nested structures, trabeculae, peripheral palisading, or rosettes) and were composed of round to polygonal cells with moderate amounts of cytoplasm. The nuclei were round with vesicular chromatin or prominent nucleoli. For large cell neuroendocrine carcinomas, diagnostic criteria included labeling with at least 1 neuroendocrine marker (chromogranin or synaptophysin, see below). Mitotic rate was determined by counting 50 HPF (at Â 400 on an Olympus microscope = 0.45 mm 2 ) and averaged to 10 HPF. The Ki67-labeling index was determined by manual counting of 1000 cells using captured images of the proliferation hot spots, as described previously. 24 Four tumors that did not label with any of the neuroendocrine or acinar markers and did not have small cell carcinoma morphology were excluded for further analysis. Seventeen tumors immunolabeled with trypsin and/or chymotrypsin in >25% of the neoplastic cells and were thus reclassified as mixed acinar-neuroendocrine carcinoma (12 tumors) or pure acinar cell carcinoma (5 tumors). 25 Of the remaining cases, 42 were excluded due to a well-differentiated NET morphology and/or a low mitotic rate (r20/ 10 HPF) and low Ki67-labeling index (r20%) ( Table 1) .
For the remaining 44 cases, the following histopathologic information was recorded: tumor size; cell type; growth pattern; necrosis; lymphovascular and perineural invasion; margin status; extension into the peripancreatic soft tissue, duodenal wall, or other adjacent organs; and number of involved lymph nodes. Also tabulated was the presence of non-neuroendocrine components such as ductal adenocarcinoma or squamous cell carcinoma. The carcinomas were staged following the criteria of the seventh edition American Joint Cancer Committee (AJCC) cancer staging manual. 26 Overall survival data were obtained from hospital records or the United States Social Security Death Index. Survival analysis was performed using the Kaplan-Meier method and log rank (Mantel-Cox) comparison, which was performed with StatView software version 5.0 (SAS Institute, Cary, NC) and/or MedCalc V12.7.5 (MedCalc Software bvba, Ostend, Belgium).
RESULTS
We identified a total of 44 cases (43 surgical specimens, 1 autopsy) that met the criteria for poorly differentiated neuroendocrine carcinoma outlined above.
Clinical Features
The mean patient age was 59 years (range, 21 to 82 y), with a male to female ratio of 1.4. The age and sex of the patients with large cell neuroendocrine carcinoma (mean age, 60.4; male to female ratio = 1.9) were similar to those of patients with small cell carcinoma (mean age, 57.5; male to female ratio = 0.9; P = 0.57 [Student t test] and P = 0.34 [Fisher exact test], respectively; Table 2 ). None of the patients had a known genetic syndrome, except for 1 patient who carried a germline BRCA1 mutation. One patient had a history of breast carcinoma and melanoma, and another had a gastric adenocarcinoma. Of 35 patients with information available, only 1 had an increased serum hormone level (hyperinsulinism). Thirty patients underwent pancreatoduodenectomy, and 11 underwent distal pancreatectomy and splenectomy. In 3 patients, the type of surgery was not known. Adjuvant therapy information was available for only 14 patients and was variable, although the majority of recent patients received cisplatin-based chemotherapy and/or radiation therapy.
Pathologic Features
Twenty-seven tumors were located in the head of the pancreas, 3 in the body, and 11 in the tail. Tumor location information was not available for 3 patients. Tumor size varied from 2 to 18 cm (median, 4 cm). Grossly, the tumors were tan-red or yellowish, solid, and were generally Poorly Differentiated NECs of the Pancreas described as "vaguely nodular," "lobulated," or "relatively circumscribed" (Fig. 1 ). Hemorrhage was common, and necrosis was occasionally noted. Microscopically, 27 carcinomas were large cell neuroendocrine carcinoma, in which the growth pattern was more variable. Diffuse, organoid/nested, trabecular ( Fig. 2A) , and peripheral palisading growth patterns, often intermingled in various proportions, were seen in most of these carcinomas. In some of the large cell neuroendocrine carcinomas, pseudopapillae, composed of viable tumor cells surrounding fibrovascular cores, were seen at the periphery of necrotic areas. Rarely, tumors displayed glandular formations (Fig. 2B ). Apoptotic cells and mitotic figures were abundant, but mitotic figures in the large cell neuroendocrine carcinomas were not as numerous as in the small cell carcinomas, averaging 37/10 HPF (range, 21 to 83 HPF). The average Ki67-labeling index in the large cell neuroendocrine carcinomas was 66% (range, 40% to 95%). The remaining 17 cases were small cell carcinomas displaying predominantly a diffuse, sheet-like growth pattern with confluent areas of necrosis and entrapment of pancreatic parenchyma. Scattered tumor giant cells with hyperchromatic, bizarre nuclei ( Fig. 3 ) or rosettes were also noted in some tumors. Extensive apoptosis was present in all small cell carcinomas, and mitoses averaged 51/10 HPF (range, 21 to 92 HPF). The average Ki67-labeling index was 75% (range, 50% to 98%).
Although the majority (36 of the 44) of the poorly differentiated neuroendocrine carcinomas was pure, 8 had combined components. An associated conventional ductal adenocarcinoma was present in 6 cases. The poorly differentiated neuroendocrine carcinoma was large cell subtype in 5 of these cases and small cell subtype in 1. Whereas the poorly differentiated neuroendocrine carcinoma and ductal adenocarcinoma components were sharply segregated in 2 cases, they merged intimately in 4 ( Fig. 4 ). Large cell neuroendocrine carcinoma arose in association with an intraductal papillary mucinous neoplasm (IPMN), pancreatobiliary type, with high-grade dysplasia in 1 case. Another case revealed sheets of small cell carcinoma admixed with squamous cell carcinoma ( Fig. 4 ).
In addition, 2 cases had regions demonstrating features of well-differentiated NET, composed of cells with moderate amounts of cytoplasm and round, regular nuclei with stippled chromatin (Fig. 5A ). In those sharply segregated well-differentiated foci, the mitotic rate was <1/10 HPF, and the Ki67-labeling index was 1% and 5%, respectively, as opposed to frequent mitotic figures, necrosis, and Ki67-labeling indices of 50% and 55%, respectively, in the associated poorly differentiated neuroendocrine carcinoma components, both of which were large cell neuroendocrine carcinomas ( Fig. 5B) .
Perineural invasion and angiolymphatic invasion were identified in the majority of the carcinomas (71% and 79%, respectively). All but 3 carcinomas extended beyond the pancreas (pT3), usually into the peripancreatic soft tissue but also into the duodenum in 5, portal vein in 3, splenic artery and vein in 1, and spleen in 1. In addition, 17 of 30 cases had 1 or more positive surgical margins; of those with information available, the posterior-inferior (uncinate) margin was involved in 9 cases, the pancreatic neck (duct) margin in 3 cases, and the proximal margin in 1 case. FIGURE 1. This large, tan-yellow, vaguely nodular, fleshy mass with areas of necrosis suggests that the lesion is not a ductal adenocarcinoma, and the differential diagnoses include poorly differentiated neuroendocrine carcinoma and acinar cell carcinoma.
Although high-grade pancreatic intraepithelial neoplasia (PanIN-3) was identified in all 6 cases with an associated adenocarcinoma component, pathologic changes in the adjacent pancreatic parenchyma, when present, were largely limited to atrophy. It should be noted, however, that in many cases little uninvolved pancreas was available for study. Metastases to regional lymph nodes and liver were common at presentation. Twenty-six patients had metastases to regional lymph nodes only; 8 had metastases to both regional lymph nodes and to the liver; and 3 had metastases to the liver only. Fifteen patients, including 3 patients without metastases at the time of diagnosis, developed (additional) metastases as the disease progressed. The majority of subsequent metastases were to the liver; however, brain, lung, mediastinum, adrenal gland, and kidney were involved in rare cases.
Immunohistochemistry
Immunohistochemically, all of the poorly differentiated neuroendocrine carcinomas labeled with at least 1 neuroendocrine marker (chromogranin and/or synaptophysin) in >10% of the tumor cells. There were 7 cases that were positive for only 1 neuroendocrine marker, emphasizing the need for both stains. Synaptophysin was more sensitive and was expressed in 95% of the cases, and chromogranin was expressed in 84%. In most cases, 30% to 75% of the tumor cells were moderately to strongly immunolabeled with neuroendocrine marker(s). The labeling was often patchy.
The acinar markers were either negative or labeled rare, scattered cells in the poorly differentiated neuroendocrine carcinomas. None of the cases tested labeled with CD99.
Clinical Course
Follow-up information was available for 43 of the 44 patients. The follow-up period ranged from 0 to 104 months (median, 9 mo), and 35 patients were followed up to the time of their death. At the last follow-up, 33 patients had died of disease, with a median survival of 11 months (range, 0 to 104 mo). One patient died of surgical complications, and another patient with disease died in an accident at 8 months. Eight patients were alive with disease at a median follow-up of 19.5 months (range, 0 to 71 mo). The 2-and 5-year disease-specific survival rates were 22.5% ± 6.9% and 16.1% ± 6.3% (mean ± standard error), respectively (Fig. 6) .
The median survival of the patients with large cell neuroendocrine carcinoma (n = 27) was longer than that of the patients with small cell carcinoma (n = 17) (16 vs. 6 mo) with overlapping 95% confidence interval; however, 2-and 5-year disease-specific survival rates (24.2% vs. 22.2% and 16.2% vs. 16 .6%, respectively) were equivalent (Table 2) . Thus, the difference in survival between these 2 groups was not statistically significant (log rank P = 0.3653). Likewise, the survival difference between pure and combined poorly differentiated neuroendocrine carcinomas (median survival, 12 vs. 20 mo; 2-and 5-year disease-specific survival rates, 21.8% vs. 25.4% and 9.1% vs. 0%, respectively) was not statistically significant (log rank P = 0.722). By Kaplan-Meier survival analysis, none of the prognostic factors tested (age, sex, tumor location, tumor size, lymphovascular and perineural invasion, margin status, T stage, lymph node metastasis) was significantly associated with survival (Table 3 ). In particular, the patients with a Ki67-labeling index <55% (n = 12, mean index = 43%) did not live longer than those with a Ki67labeling index Z55% (n = 26, mean index = 79%).
DISCUSSION
The current WHO classification of gastroenteropancreatic neuroendocrine neoplasms, 1 which is based on the 2007 proposals from the European Neuroendocrine Tumor Society, 27 recommends the use of proliferative rate-based grading to separate the neoplasms into 3 grades, with the highest grade (grade 3) stated to correspond to poorly differentiated neuroendocrine carcinomas (small cell carcinoma and large cell neuroendocrine carcinoma). Although several recent studies have verified the prognostic significance of the WHO system, 28, 29 the threshold of 20 mitoses per 10 HPF or 20% Ki67-labeling index used to separate grade 2 (ie, well-differentiated NETs) from grade 3 has been questioned. Anecdotal experience suggests that some NETs that are histologically well differentiated may have a proliferative rate somewhat in excess of these cutoff points. 30 The current study was conducted to specifically evaluate those pancreatic neuroendocrine neoplasms that have both histologic features of a poorly differentiated carcinoma and a high proliferative rate (both mitotic rate and Ki67 index above the threshold)-the "true" poorly differentiated neuroendocrine carcinomas. Cases with a well-differentiated morphology but an elevated proliferative rate, which fell in the grade 3 category solely on the basis of the Ki67 index, were therefore excluded. The term "poorly differentiated" neuroendocrine carcinoma is used deliberately to specify this group, in distinction to "high-grade" neuroendocrine carcinoma, which includes all neoplasms currently within the WHO grade 3 category.
This study constitutes the largest series of histologically confirmed, primary pancreatic poorly differentiated neuroendocrine carcinoma, a neoplasm whose pathologic features have not been analyzed in detail. A larger collection of grade 3 primary pancreatic neuroendocrine neoplasms was reported by Sorbye et al (The Nordic neuroendocrine carcinoma study) 11 ; however, their study mainly focused on treatment aspects without a detailed description of the pathologic characteristics. In addition, some of their findings, such as a Ki67 index Z55% in only 30% of their pancreatic high-grade neuroendocrine carcinomas (vs. 60% in our study), suggest that some of their cases were likely well-differentiated NETs with an elevated proliferative rate, rather than poorly differentiated neuroendocrine carcinomas as defined in our study.
Most of the patients in this series were in their late 50s, and there was a slight male predilection (male/female ratio of 1.4). In contrast to well-differentiated NETs, the poorly differentiated carcinomas were not associated with hereditary syndromes and were clinically nonfunctional. Most arose in the head of the pancreas and presented as a large (median tumor size of 4 cm), relatively circumscribed, solid mass. The small cell subtype was less common than the large cell subtype (39% vs. 61%).
Review of these cases culled from the archives of many institutions clearly demonstrates that the accurate diagnosis of pancreatic poorly differentiated neuroendocrine carcinoma can be challenging. Entities prominent in the differential diagnosis include well-differentiated NETs, acinar cell carcinoma, mixed acinar-neuroendocrine carcinomas, 25, 31, 32 and primitive neuroectodermal tumor (PNET). 33 The histologic features of these entities can overlap significantly, but immunohistochemical staining can usually establish the correct diagnosis if all possibilities are considered. Table 4 includes some of the distinguishing histologic findings, along with the results of targeted immunohistochemical labeling that can be used to correctly classify these neoplasms.
In our study, the potential for poorly differentiated neuroendocrine carcinomas to be misdiagnosed as welldifferentiated NETs was not assessed, as our search parameters targeted only cases originally diagnosed as poorly differentiated or high grade. However, in our experience, this scenario is not common, as the necrosis, nuclear atypia, and high proliferative rate of poorly differentiated neuroendocrine carcinomas are usually readily recognizable. The converse diagnostic confusion is much more common; indeed, in our study, 42 cases originally diagnosed as poorly 35 and features such as a diffuse or markedly infiltrative growth pattern and necrosis can also be identified. 19 On casual examination, these falsely suggest a poorly differentiated neoplasm, but it is the proliferative rate that defines a neuroendocrine neoplasm to be poorly differentiated. 1 If careful mitotic count and immunolabeling for Ki67 are not performed, misclassification can occur, which can have profound therapeutic consequences. 36 More importantly, recently, it has become clear that some well-differentiated NETs may have a proliferative rate in excess of the threshold established by the WHO for high-grade (grade 3) neuroendocrine carcinomas. 21, 30 Although detailed pathologic studies of this group are still underway, the available evidence suggests that these NETs are genetically and biologically more closely related to low-grade and intermediate-grade (grades 1 and 2) NETs than to poorly differentiated neuroendocrine carcinomas. 37 The "Nordic neuroendocrine carcinoma study" has also shown that "high-grade" neuroendocrine carcinomas with a Ki67labeling index <55% did not respond to platinum-based chemotherapy, in contrast to those with a Ki67-labeling index >55%, 11 supporting the concept that the tumors that are at the lower end of the grade 3 range are in fact welldifferentiated NETs with an elevated proliferative rate (or "high-grade well-differentiated NETs"). It is noteworthy that there was no survival difference between poorly differentiated neuroendocrine carcinomas with Ki67-labeling index <55% vs. Z55% in our study (Table 3) , as we excluded the highly proliferative well-differentiated NETs (5, 16) that likely impacted the outcome and therapeutic responsiveness of the <55% group in that study. Furthermore, our group has recently demonstrated that the outcome of well-differentiated NETs with an elevated proliferative rate is worse than that of intermediate-grade well-differentiated NETs but not as poor as that of the poorly differentiated neuroendocrine carcinomas (5-year disease-specific survival rates of 22% vs. 60.5% vs. 17%, respectively). 21 Obviously, careful assessment of the proliferative rate is necessary to separate these tumor types, and recognition of a more organoid growth pattern, more limited necrosis, and more classic neuroendocrine nuclear features would favor a diagnosis of well-differentiated NET.
Much has been written about the distinction of acinar cell carcinomas and the related mixed acinar carcinomas (mixed acinar-neuroendocrine carcinoma in particular) from well-differentiated NETs. 19, 38 The presence of acinar formations, basal nuclear polarization, granular eosinophilic cytoplasm, and solitary large nucleoli all favor a diagnosis of an acinar neoplasm. Confirmation of acinar differentiation with immunohistochemical stains for trypsin and chymotrypsin is important to establish the diagnosis. Another feature more typical of acinar cell carcinoma and mixed acinar carcinomas, relative to well-differentiated NETs, is a high proliferative rate, as these acinar neoplasms commonly (but not always) have a mitotic rate >20/10 HPF and a Ki67-labeling index of 30% to 60%. However, as our study demonstrates, the distinction of acinar cell carcinoma and mixed acinar carcinomas from poorly differ-entiated neuroendocrine carcinomas is even more problematic. Both entities usually have a high proliferative rate, acinar cell carcinomas can have a diffuse growth pattern and can lack the distinguishing features mentioned above, and large cell-type poorly differentiated neuroendocrine carcinomas can have prominent nucleoli. In our study, 17 cases originally diagnosed as poorly differentiated neuroendocrine carcinomas proved to be acinar cell carcinomas or mixed acinar-neuroendocrine carcinomas on our review. Although cytologic features suggesting acinar differentiation were found in some cases, there were also cases in which no distinguishing characteristics could be recognized, and the finding of immunolabeling for chromogranin or synaptophysin in some cases wrongly suggested a pure poorly differentiated neuroendocrine carcinoma. In all of these cases, immunohistochemical staining for trypsin and chymotrypsin had not been performed, and the correct diagnosis was readily established once these stains were completed. Given the rarity of primary pancreatic poorly differentiated neuroendocrine carcinomas, relative to acinar neoplasms, it is thus recommended that a diagnosis of poorly differentiated neuroendocrine carcinoma should not be rendered unless acinar differentiation has been excluded immunohistochemically.
A final diagnostic consideration is PNET, especially in younger patients. PNETs generally have small, round, monotonous nuclei with inconspicuous nucleoli and scant cytoplasm, although pancreatic examples can be more epithelioid and can express keratin strongly. 33 The 34 but in the cases of poorly differentiated neuroendocrine carcinoma with suggestive morphology in the current study, CD99 stains were consistently negative. In questionable cases, molecular studies can be carried out to further explore this diagnosis. Consistent with previous reports, the pancreatic poorly differentiated neuroendocrine carcinomas in this study behaved aggressively, commonly featuring vascular and perineural invasion and lymph node metastases, with dismal survival. The overall median survival was only 12 months, and 77% of the patients died of disease after a mean follow-up of <1 year, despite presenting with resectable disease. Similar to the recent European multicenter study, 11 there was no difference in survival among the morphologic subtypes of poorly differentiated neuroendocrine carcinoma (small cell carcinoma vs. large cell neuroendocrine carcinoma).
Eight (18%) of our cases contained neoplastic elements of non-neuroendocrine lineage, usually ductal adenocarcinomas or a precursor thereof (IPMN). The presence of an associated adenocarcinoma, IPMN, or squamous cell carcinoma component also was not associated with different survival. In most cases, these elements were mixed throughout the tumor, and, although molecular studies to prove their relationship have yet to be performed, we suspect that the glandular or squamous components of these combined carcinomas share a common histogenesis. Similar combinations exist in poorly differentiated neuroendocrine carcinomas of other organs, such as the lung 39 and large bowel, 8 in which non-neuroendocrine elements are found in >40% of carefully examined cases. Insufficient treatment response data exist to determine whether the biology of the poorly differentiated neuroendocrine carcinoma component should dictate the choice of chemotherapy in the pancreas, but in other sites, these combined carcinomas are generally managed as neuroendocrine carcinomas.
As survival differences between the different morphologic types of pancreatic poorly differentiated neuroendocrine carcinoma are minimal, an obvious question is whether there is a need to separate small cell carcinoma from large cell neuroendocrine carcinoma for clinical management. Currently, we believe that the evidence is still insufficient to justify combining the subtypes into a single entity, despite the admitted difficulty of distinguishing them in cases with borderline nuclear features. Although the management of large cell neuroendocrine carcinomas of several anatomic sites has been extrapolated from that of small cell carcinoma, the evidence that platinum-based chemotherapy is the optimal choice for large cell neuroendocrine carcinoma is not compelling. 40 The characteristic dramatic responses seen in small cell carcinomas are not common in large cell neuroendocrine carcinomas, and randomized clinical trials to prove the benefit of platinumbased chemotherapy have yet to be conducted.
Another goal of this study was to reassess the mitotic rate and Ki67 index thresholds used to separate grade 2 well-differentiated NETs from grade 3 neuroendocrine carcinomas, as the cutoff points of 20 mitoses per 10 HPF and Ki67 of 20% have been questioned. Our results demonstrated that when only the pancreatic neuroendocrine neoplasms with poorly differentiated morphologic features are considered, both the mitotic rate (average, 51 and 37 per 10 HPF for small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma, respectively) and Ki67 index (average, 75% and 66% for small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma, respectively) are much higher than the WHO-recommended thresholds for the grade 3 category. Thus, if the intent of the grade 3 category is to capture only the poorly differentiated neuroendocrine neoplasm, the cutoff points for this grade could be raised. Whether the well-differentiated NETs that currently fall in the grade 3 category should continue to be separated from grade 2 well-differentiated NETs requires further study.
Finally, the potential relationship of poorly differentiated neuroendocrine carcinomas to well-differentiated NETs has been a subject of debate. Although it is rare to encounter a poorly differentiated neuroendocrine carcinoma arising in association with a well-differentiated NET, neoplastic progression of well-differentiated NETs has been proposed as the origin of some poorly differentiated neuroendocrine carcinomas of the pancreas. 19, 41 However, it has been shown recently that pancreatic small cell carcinoma and large cell neuroendocrine carcinoma are genetically related entities and that the genetic changes frequently seen in these neoplasms, such as coinactivation of the TP53 and the Rb/p16 cell cycle pathways, are infrequently observed in pancreatic well-differentiated NETs. 22 Conversely, inactivating mutations in DAXX and ATRX and mutations in MEN1 are exclusively found in pancreatic well-differentiated NETs but not in small cell carcinoma or large cell neuroendocrine carcinoma of the pancreas. 22 Although these findings suggest that poorly differentiated neuroendocrine carcinoma is a genetically distinct entity from well-differentiated NETs, it does not fully rule out the possibility that pancreatic well-differentiated NETs may rarely transform genetically into poorly differentiated neuroendocrine carcinomas. 19 In fact, in our study, 5% of the poorly differentiated neuroendocrine carcinomas arose in a background of well-differentiated (WHO grades 1 and 2) NETs. Although the frequency with which pancreatic well-differentiated NETs may transform to true poorly differentiated neuroendocrine carcinomas is unknown, most observations to date suggest that it is an uncommon pathway for the development of pancreatic poorly differentiated neuroendocrine carcinoma. However, progression of grade 1 well-differentiated NETs to higher-grade well-differentiated NETs does occur with greater frequency, and this topic is the subject of ongoing research. 37 In summary, this study illustrates the pathologic characteristics of diagnostically challenging primary pancreatic poorly differentiated neuroendocrine carcinomas.
These are uncommon, highly aggressive neoplasms that are often locally advanced at the time of diagnosis and have a dismal prognosis. Distinction of these carcinomas from their mimics and application of current grading parameters will allow more consistent treatment decisions to help better understand their biology and optimal management.
